Vm. Steen et al., DETECTION OF THE POOR METABOLIZER-ASSOCIATED CYP2D6(D) GENE DELETION ALLELE BY LONG-PCR TECHNOLOGY, Pharmacogenetics, 5(4), 1995, pp. 215-223
The cytochrome P450 enzyme debrisoquine 4-hydroxylase metabolizes many
different classes of commonly used drugs, such as antidepressants and
neuroleptics. Deficient hydroxylation of debrisoquine, known as the p
oor metabolizer (PM) phenotype, affects 5-10% of Caucasians and may le
ad to adverse reactions upon administration of drugs in standard doses
. This autosomal recessive metabolic deficiency is caused by the posse
ssion of two PM-associated mutations in the human CYP2D6 gene locus co
ding for the enzyme. These mutations include at least four different s
ingle base mutations and two different large gene deletion alleles, Th
e single base mutations can be rapidly detected by PCR methods. In con
trast, the large gene deletions have so far only been directly identif
ied by RFLP analysis, By the use of sequence data previously published
by others, we report here an alignment of different CYP2D alleles to
focus on the presence of almost completely identical sequences immedia
tely downstream of both CYP2D7 and CYP2D6 which may seriously complica
te and interfere with PCR-based detection of the gene deletion. Based
on this analysis, we have developed a rapid assay which, for the first
time, detects the 13kb (also called 11.5 kb) Xba I gene deletion alle
le by the use of long-PCR technology. The primers were designed to amp
lify a 3.5 kb PCR product in the presence of this D6(D) allele. We hav
e evaluated the method on 23 different DNA samples heterozygous (n = 2
2) or homozygous (n = 1) for the 13 kb gene deletion allele (previousl
y typed by RFLP analyses). All samples were correctly identified by th
e assay, The PCR method did not detect the rare 11 kb Xba I gene delet
ion allele (n = 5), and there was no false positive amplification from
deletion negative DNA samples (n = 47). This sensitive and specific P
CR-based assay for detection of the D6(D) allele will improve the scie
ntific and clinical use of CYP2D6 genotyping.